Big news: This vaccine can give 100 percent protection against severe corona infection, this company claims


Experts are seeing vaccination as the most effective way to protect against coronavirus. In this sequence, the vaccination campaign has been intensified all over the world. Vaccine makers Many companies are still working rapidly towards manufacturing effective vaccines so that the demand for vaccines can be met worldwide as soon as possible. Meanwhile, on Monday, the American biotechnology company, Novavax, has claimed 90 percent of its vaccine against Corona. Biotech firm Novavax has reported that its Kovid-19 vaccine (NVX-CoV2373) is up to 93 percent effective even on delta variants of concern worldwide.

After this announcement of Novavax, now it is expected to strengthen the competition with the infection. Let us know more important things related to the vaccine in this article.

What is the company's claim?

Through a tweet on Monday, Novavax said that the total efficacy of the vaccine has been found to be close to 90 percent in the Phase-3 trial. Not only this, but it can also provide up to 100 protection against moderate and severe disease of the corona. Releasing the Phase III trial details, the company said that this vaccine can prove to be very effective in terms of protection from the corona.

Good signs seen in clinical trials

The company said that it is planning to apply to the Food and Drug Administration for authorization of the vaccine in the third quarter of this year (after September). Stanley C. Erck, President, and CEO of Novavax said, "Today the company has taken a step forward in the fight against COVID-19. The clinical results show that this vaccine (NVX-CoV2373) will prove to be highly effective, as well as providing complete protection against moderate and severe infections of COVID-19.

Good results expected even in high-risk populations

In a statement issued by the company, it has been told that this vaccine is expected to provide good results even in high-risk populations. A high-risk population means people above 65 years of age with comorbidities. To know the efficacy of the vaccine, the company included 29,960 participants from 119 cities in the US and Mexico. After the study, scientists said that better results have been seen from the protective point of view of the vaccine.

People's hope is related to the vaccine

George M. Glenn, president of research and development at Novavax, says the vaccine data so far shows a high level of efficacy. Our vaccine can play an important role in the worldwide fight against COVID-19. The data regarding the effectiveness of the vaccine is quite comforting. A plan is being worked out to make the vaccine available to the public soon after all necessary actions are completed.

Disclaimer: The Information and notifications given in this article are based on assumptions. does not confirm these. Contact the concerned specialist before implementing them. Comment for the questions related to this news and tell us to read such news, do not forget to follow us - thank you